The FDA has filed the NDA submission for relacorilant to treat patients with Cushing syndrome (hypercortisolism).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback